Synergy Spine Solutions, an innovative orthopaedic medical devices developer focused on artificial cervical disc replacement, today announced it has entered into a sales agency agreement with DePuy Synthes Spine (DPS) to expand access to the company’s marquis technology, the Synergy Disc®, in the United Kingdom.
The Synergy Disc® is the only artificial cervical disc with a 6° lordotic core that combines cervical alignment and balance with natural motion for patients with degenerative disc disease (DDD) causing radiculopathy and / or myelopathy.
The unique design of the Synergy Disc utilises time-tested materials that are aligned with the stringent standards of DPS and their role as a global leader in orthopaedic and spine technology.
The multi-year collaboration between Synergy and DPS combines a top tier product with a market leader in spine sales and is forged to accelerate the cervical disc arthroplasty market in the UK.
Both companies look forward to working together to deliver this exciting technology to spine surgeons as they work to improve their patients’ quality of life and advance the standard of care.
“It is fantastic that two organisations committed to excellence and innovation can collaborate to increase surgeons’ and patients’ access to the Synergy Disc in the UK,” said Synergy Spine Solutions CEO Josh Butters.
“We are excited about this new engagement with DPS and look forward to working together to advance the standard of care and expand the overall awareness of motion preservation procedures in the cervical spine.”
Notes to Editors:
Synergy Spine Solutions
The Vision of Synergy Spine Solutions is to identify and commercialize innovative spine technologies that help surgeons improve their patients’ quality of life and advance the standard of care. The company’s flagship product, the Synergy Disc®, is the only device that is designed to restore both motion and alignment to the spine.
The Synergy Disc® is currently commercially available in various territories in APAC and EMEA regions including Australia, UK and Germany as well as in Canada via SAP. In the United States, the Synergy Disc is investigational use only and Synergy is currently enrolling patients in its IDE study.
VP of Sales and Marketing